We are live on ! Find out more
PGP

Prescott General Partners Portfolio holdings

AUM $1.37B
1-Year Est. Return 23.81%
This Fund
S&P 500
This Quarter Est. Return
-26.21%
1 Year Est. Return
+23.81%
3 Year Est. Return
+67.15%
5 Year Est. Return
+9.62%
10 Year Est. Return
+525.75%
AUM
$1.46B
AUM Growth
-$737M
Cap. Flow
-$47.9M
Cap. Flow %
-3.29%
Top 10 Hldgs %
99.95%
Holding
13
New
1
Increased
Reduced
3
Closed
1

Top Buys

Rank Stock Value
1
ALT icon
Altimmune
ALT
+$308K

Top Sells

Rank Stock Value
1
CACC icon
Credit Acceptance
CACC
+$41.2M
2
ME
23andMe Holding Co
ME
+$5.45M
3
SANA icon
Sana Biotechnology
SANA
+$1.23M
4
HUMA icon
Humacyte
HUMA
+$316K

Sector Composition

Rank Sector Weight
1 Financials 68.75%
2 Industrials 13.4%
3 Consumer Discretionary 11.43%
4 Communication Services 5.55%
5 Healthcare 0.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CACC icon
1
Credit Acceptance
CACC
$5.94B
$773M 53.05%
1,632,368
-74,637
-4% -$41.2M
WRLD icon
2
World Acceptance Corp
WRLD
$837M
$229M 15.7%
2,037,495
W icon
3
Wayfair
W
$11.5B
$167M 11.43%
3,823,239
CMPR icon
4
Cimpress
CMPR
$2.37B
$152M 10.43%
3,906,492
YELP icon
5
Yelp
YELP
$1.45B
$80.8M 5.55%
2,909,751
GIC icon
6
Global Industrial
GIC
$1.36B
$43.2M 2.97%
1,279,677
VAPO
7
DELISTED
Vapotherm, Inc. Common Stock
VAPO
$6.47M 0.44%
319,655
LCTX icon
8
Lineage Cell Therapeutics
LCTX
$272M
$2.93M 0.2%
1,851,851
HUMA icon
9
Humacyte
HUMA
$178M
$1.82M 0.13%
568,246
-56,854
-9% -$316K
SANA icon
10
Sana Biotechnology
SANA
$865M
$785K 0.05%
122,097
-193,703
-61% -$1.23M
ALT icon
11
Altimmune
ALT
$543M
$585K 0.04%
+50,000
New +$308K
SER icon
12
Serina Therapeutics
SER
$30.6M
$107K 0.01%
5,265
ME
13
DELISTED
23andMe Holding Co
ME
-71,191
Closed -$5.45M

Similar funds

Prescott General Partners's Q2 2022 Portfolio in Review

As of Q2 2022, Prescott General Partners held 13 positions worth $1.46B, down 34% from $2.19B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Prescott General Partners withdrew a net $47.9M in Q2 2022, closing 1 position and reducing 3 holdings. Its most notable exit was 23andMe Holding Co, an estimated $5.45M position sold in full.

By sector, the portfolio is most concentrated in Financials at 69% of assets, up from 61% a quarter earlier, followed by Industrials and Consumer Discretionary.

Against the trend, Prescott General Partners opened a new position in Altimmune worth $585K.

  • Prescott General Partners's largest Q2 2022 buy was Altimmune: 50,000 shares worth $585K.
  • Prescott General Partners's biggest Q2 2022 reduction was Credit Acceptance, cutting an estimated $41.2M.
  • Prescott General Partners fully exited 23andMe Holding Co in Q2 2022, selling an estimated $5.45M.
  • Prescott General Partners's ten largest holdings make up 100% of its $1.46B portfolio in Q2 2022.
  • Prescott General Partners opened 1 new position and closed 1 in Q2 2022.
  • Prescott General Partners's portfolio value fell 34% quarter-over-quarter to $1.46B.

Based on Prescott General Partners's 13F filing for Q2 2022, filed 15 Aug 2022.